{"product_id":"garetosmab-regn2477-10mg","title":"Garetosmab (REGN2477) 10mg","description":"\u003carticle data-turn=\"user\" data-scroll-anchor=\"false\" data-testid=\"conversation-turn-21\" data-turn-id=\"18bb535b-a8eb-4575-8fff-5c3c862f39a4\" dir=\"auto\" class=\"text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto scroll-mt-(--header-height)\" tabindex=\"-1\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pt-12 [--thread-content-margin:--spacing(4)] @w-sm\/main:[--thread-content-margin:--spacing(6)] @w-lg\/main:[--thread-content-margin:--spacing(16)] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col\" tabindex=\"-1\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col grow\"\u003e\n\u003cdiv class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal [.text-message+\u0026amp;]:mt-1\" dir=\"auto\" data-message-id=\"18bb535b-a8eb-4575-8fff-5c3c862f39a4\" data-message-author-role=\"user\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden items-end rtl:items-start\"\u003e\n\u003cdiv class=\"user-message-bubble-color corner-superellipse\/1.1 relative rounded-[18px] px-4 py-1.5 data-[multiline]:py-3 max-w-[var(--user-chat-width,70%)]\"\u003e\n\u003cdiv class=\"whitespace-pre-wrap\"\u003e\n\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eDue to the nature of this product being a monoclonal antibody and thus must be manufactured and stored under stringent quality standards, order fulfillment requires additional processing time. Please allow 2–3 weeks for production, plus shipping time, to ensure we deliver a product that meets our quality and purity specifications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-pm-slice=\"1 1 []\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle data-turn=\"assistant\" data-scroll-anchor=\"true\" data-testid=\"conversation-turn-22\" data-turn-id=\"request-67dd8ee4-ae78-8005-a0c3-b28c8a99a833-3\" dir=\"auto\" class=\"text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" tabindex=\"-1\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-10 [--thread-content-margin:--spacing(4)] @w-sm\/main:[--thread-content-margin:--spacing(6)] @w-lg\/main:[--thread-content-margin:--spacing(16)] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\" tabindex=\"-1\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col grow\"\u003e\n\u003cdiv data-message-model-slug=\"gpt-5-2\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal [.text-message+\u0026amp;]:mt-1\" dir=\"auto\" data-message-id=\"758e621d-b469-4696-a280-372ab763f114\" data-message-author-role=\"assistant\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[1px]\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert w-full wrap-break-word light markdown-new-styling\"\u003e\n\u003ch2 data-end=\"55\" data-start=\"0\"\u003eGaretosmab (REGN2477)\u003c\/h2\u003e\n\u003chr data-end=\"60\" data-start=\"57\"\u003e\n\u003cp data-end=\"556\" data-start=\"81\"\u003e\u003cstrong data-end=\"95\" data-start=\"81\"\u003eGaretosmab\u003c\/strong\u003e is a \u003cstrong data-end=\"136\" data-start=\"101\"\u003efully human monoclonal antibody\u003c\/strong\u003e developed by Regeneron that \u003cstrong data-end=\"190\" data-start=\"165\"\u003eneutralizes activin A\u003c\/strong\u003e, a TGF-β superfamily ligand involved in \u003cstrong data-end=\"312\" data-start=\"231\"\u003emuscle wasting, inflammation, fibrosis, bone metabolism, and iron homeostasis\u003c\/strong\u003e. It was initially developed for \u003cstrong data-end=\"392\" data-start=\"345\"\u003efibrodysplasia ossificans progressiva (FOP)\u003c\/strong\u003e and has more recently been repurposed into \u003cstrong data-end=\"498\" data-start=\"436\"\u003ebody-composition and metabolic-health combination programs\u003c\/strong\u003e (notably with GLP-1 receptor agonists and trevogrumab).\u003c\/p\u003e\n\u003cp data-end=\"834\" data-start=\"559\"\u003e\u003cstrong data-end=\"579\" data-start=\"559\"\u003eKey positioning:\u003c\/strong\u003e Unlike broad ActRIIB-trap approaches, garetosmab is \u003cstrong data-end=\"666\" data-start=\"632\"\u003eligand-selective for activin A\u003c\/strong\u003e, designed to avoid global suppression of multiple TGF-β ligands that can drive unwanted effects (e.g., vascular, reproductive, or oncogenic signaling perturbations).\u003c\/p\u003e\n\u003chr data-end=\"840\" data-start=\"837\"\u003e\n\u003ch2 data-end=\"900\" data-start=\"842\"\u003e2) Why activin A matters: target biology in one slide\u003c\/h2\u003e\n\u003cp data-end=\"1074\" data-start=\"901\"\u003e\u003cstrong data-end=\"914\" data-start=\"901\"\u003eActivin A\u003c\/strong\u003e (INHBA) is a pleiotropic cytokine within the TGF-β superfamily that signals primarily through \u003cstrong data-end=\"1045\" data-start=\"1009\"\u003eActRIIA\/ActRIIB → ALK4 → SMAD2\/3\u003c\/strong\u003e pathways. Its biology spans:\u003c\/p\u003e\n\u003cul data-end=\"1494\" data-start=\"1076\"\u003e\n\u003cli data-end=\"1183\" data-start=\"1076\"\u003e\n\u003cp data-end=\"1183\" data-start=\"1078\"\u003e\u003cstrong data-end=\"1089\" data-start=\"1078\"\u003eMuscle:\u003c\/strong\u003e promotes catabolism, impairs regeneration, and synergizes with myostatin in driving atrophy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1257\" data-start=\"1184\"\u003e\n\u003cp data-end=\"1257\" data-start=\"1186\"\u003e\u003cstrong data-end=\"1195\" data-start=\"1186\"\u003eBone:\u003c\/strong\u003e regulates osteoclastogenesis and osteoblast differentiation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1344\" data-start=\"1258\"\u003e\n\u003cp data-end=\"1344\" data-start=\"1260\"\u003e\u003cstrong data-end=\"1273\" data-start=\"1260\"\u003eFibrosis:\u003c\/strong\u003e pro-fibrotic signaling in lung, liver, muscle, and connective tissue\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1415\" data-start=\"1345\"\u003e\n\u003cp data-end=\"1415\" data-start=\"1347\"\u003e\u003cstrong data-end=\"1364\" data-start=\"1347\"\u003eInflammation:\u003c\/strong\u003e immune modulation and cytokine network crosstalk\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1494\" data-start=\"1416\"\u003e\n\u003cp data-end=\"1494\" data-start=\"1418\"\u003e\u003cstrong data-end=\"1438\" data-start=\"1418\"\u003eIron metabolism:\u003c\/strong\u003e suppresses hepcidin via BMP-SMAD pathway interactions\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1598\" data-start=\"1496\"\u003eThis makes activin A an unusually “high-leverage” ligand—but also a \u003cstrong data-end=\"1582\" data-start=\"1564\"\u003erisk-sensitive\u003c\/strong\u003e one to inhibit.\u003c\/p\u003e\n\u003chr data-end=\"1603\" data-start=\"1600\"\u003e\n\u003ch2 data-end=\"1642\" data-start=\"1605\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"1683\" data-start=\"1644\"\u003e3.1 Ligand-level pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"2098\" data-start=\"1684\"\u003e\n\u003cli data-end=\"1808\" data-start=\"1684\"\u003e\n\u003cp data-end=\"1808\" data-start=\"1686\"\u003e\u003cstrong data-end=\"1747\" data-start=\"1686\"\u003eGaretosmab binds circulating and locally active activin A\u003c\/strong\u003e, preventing engagement with \u003cstrong data-end=\"1805\" data-start=\"1776\"\u003eActRIIA\/ActRIIB receptors\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1962\" data-start=\"1809\"\u003e\n\u003cp data-end=\"1962\" data-start=\"1811\"\u003eThis suppresses downstream \u003cstrong data-end=\"1865\" data-start=\"1838\"\u003eSMAD2\/3 phosphorylation\u003c\/strong\u003e, thereby reducing transcription of catabolic, fibrotic, and osteogenic-dysregulation programs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2098\" data-start=\"1963\"\u003e\n\u003cp data-end=\"2098\" data-start=\"1965\"\u003eBecause activin A acts both endocrinologically and paracrinely, ligand neutralization has \u003cstrong data-end=\"2097\" data-start=\"2055\"\u003esystemic and tissue-local consequences\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"2138\" data-start=\"2100\"\u003e3.2 Systems-biology consequences\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2647\" data-start=\"2140\"\u003e\n\u003cthead data-end=\"2195\" data-start=\"2140\"\u003e\n\u003ctr data-end=\"2195\" data-start=\"2140\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"2149\" data-start=\"2140\"\u003eDomain\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"2170\" data-start=\"2149\"\u003eExpected Direction\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"2195\" data-start=\"2170\"\u003eMechanistic Rationale\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2647\" data-start=\"2251\"\u003e\n\u003ctr data-end=\"2363\" data-start=\"2251\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2269\" data-start=\"2251\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003ctd data-end=\"2290\" data-start=\"2269\" data-col-size=\"sm\"\u003e↑ mass \/ ↓ wasting\u003c\/td\u003e\n\u003ctd data-end=\"2363\" data-start=\"2290\" data-col-size=\"md\"\u003eRemoves activin-driven catabolic tone; complements myostatin blockade\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2421\" data-start=\"2364\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2375\" data-start=\"2364\"\u003eFibrosis\u003c\/td\u003e\n\u003ctd data-end=\"2379\" data-start=\"2375\" data-col-size=\"sm\"\u003e↓\u003c\/td\u003e\n\u003ctd data-end=\"2421\" data-start=\"2379\" data-col-size=\"md\"\u003eReduces pro-fibrotic SMAD2\/3 signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2500\" data-start=\"2422\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2440\" data-start=\"2422\"\u003eBone remodeling\u003c\/td\u003e\n\u003ctd data-end=\"2460\" data-start=\"2440\" data-col-size=\"sm\"\u003eContext-dependent\u003c\/td\u003e\n\u003ctd data-end=\"2500\" data-start=\"2460\" data-col-size=\"md\"\u003eAlters osteoclast\/osteoblast balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2581\" data-start=\"2501\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2519\" data-start=\"2501\"\u003eIron metabolism\u003c\/td\u003e\n\u003ctd data-end=\"2532\" data-start=\"2519\" data-col-size=\"sm\"\u003e↑ hepcidin\u003c\/td\u003e\n\u003ctd data-end=\"2581\" data-start=\"2532\" data-col-size=\"md\"\u003eRemoves activin-mediated hepcidin suppression\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2647\" data-start=\"2582\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2597\" data-start=\"2582\"\u003eInflammation\u003c\/td\u003e\n\u003ctd data-end=\"2601\" data-start=\"2597\" data-col-size=\"sm\"\u003e↓\u003c\/td\u003e\n\u003ctd data-end=\"2647\" data-start=\"2601\" data-col-size=\"md\"\u003eDampens pro-inflammatory cytokine cascades\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2652\" data-start=\"2649\"\u003e\n\u003ch2 data-end=\"2701\" data-start=\"2654\"\u003e4) Pharmacokinetics \u0026amp; exposure engineering\u003c\/h2\u003e\n\u003cp data-end=\"2809\" data-start=\"2703\"\u003eAs a fully human IgG monoclonal antibody, garetosmab displays \u003cstrong data-end=\"2808\" data-start=\"2765\"\u003eclass-typical antibody pharmacokinetics\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"3066\" data-start=\"2811\"\u003e\n\u003cli data-end=\"2873\" data-start=\"2811\"\u003e\n\u003cp data-end=\"2873\" data-start=\"2813\"\u003e\u003cstrong data-end=\"2823\" data-start=\"2813\"\u003eRoute:\u003c\/strong\u003e intravenous or subcutaneous (program-dependent)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2945\" data-start=\"2874\"\u003e\n\u003cp data-end=\"2945\" data-start=\"2876\"\u003e\u003cstrong data-end=\"2893\" data-start=\"2876\"\u003eDistribution:\u003c\/strong\u003e limited to vascular and interstitial compartments\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3013\" data-start=\"2946\"\u003e\n\u003cp data-end=\"3013\" data-start=\"2948\"\u003e\u003cstrong data-end=\"2962\" data-start=\"2948\"\u003eClearance:\u003c\/strong\u003e reticuloendothelial proteolysis + FcRn recycling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3066\" data-start=\"3014\"\u003e\n\u003cp data-end=\"3066\" data-start=\"3016\"\u003e\u003cstrong data-end=\"3030\" data-start=\"3016\"\u003eHalf-life:\u003c\/strong\u003e multi-week range (study-specific)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"3197\" data-start=\"3068\"\u003ePK and exposure–response modeling were extensively characterized in the FOP program to balance \u003cstrong data-end=\"3196\" data-start=\"3163\"\u003eligand suppression vs. safety\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-end=\"3202\" data-start=\"3199\"\u003e\n\u003ch2 data-end=\"3245\" data-start=\"3204\"\u003e5) Clinical development and evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"3300\" data-start=\"3247\"\u003e5.1 Fibrodysplasia ossificans progressiva (FOP)\u003c\/h3\u003e\n\u003cp data-end=\"3548\" data-start=\"3301\"\u003eGaretosmab was originally developed to treat \u003cstrong data-end=\"3353\" data-start=\"3346\"\u003eFOP\u003c\/strong\u003e, a rare genetic disorder characterized by progressive heterotopic ossification (HO). The rationale was that activin A aberrantly activates mutant ACVR1 receptors, driving ectopic bone formation.\u003c\/p\u003e\n\u003cul data-end=\"3857\" data-start=\"3550\"\u003e\n\u003cli data-end=\"3660\" data-start=\"3550\"\u003e\n\u003cp data-end=\"3660\" data-start=\"3552\"\u003e\u003cstrong data-end=\"3579\" data-start=\"3552\"\u003ePhase 2 LUMINA-1 trial:\u003c\/strong\u003e demonstrated \u003cstrong data-end=\"3636\" data-start=\"3593\"\u003esubstantial suppression of HO formation\u003c\/strong\u003e by imaging endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3857\" data-start=\"3661\"\u003e\n\u003cp data-end=\"3721\" data-start=\"3663\"\u003eHowever, \u003cstrong data-end=\"3709\" data-start=\"3672\"\u003eunexpected safety signals emerged\u003c\/strong\u003e, including:\u003c\/p\u003e\n\u003cul data-end=\"3857\" data-start=\"3724\"\u003e\n\u003cli data-end=\"3773\" data-start=\"3724\"\u003e\n\u003cp data-end=\"3773\" data-start=\"3726\"\u003eincreased risk of \u003cstrong data-end=\"3773\" data-start=\"3744\"\u003eepistaxis, telangiectasia\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3823\" data-start=\"3776\"\u003e\n\u003cp data-end=\"3823\" data-start=\"3778\"\u003econcerns around \u003cstrong data-end=\"3823\" data-start=\"3794\"\u003ereproductive-axis effects\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3857\" data-start=\"3826\"\u003e\n\u003cp data-end=\"3857\" data-start=\"3828\"\u003eoff-target vascular effects\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"3972\" data-start=\"3859\"\u003eThese findings led Regeneron to \u003cstrong data-end=\"3942\" data-start=\"3891\"\u003ediscontinue garetosmab as a chronic FOP therapy\u003c\/strong\u003e, despite biological efficacy.\u003c\/p\u003e\n\u003chr data-end=\"3977\" data-start=\"3974\"\u003e\n\u003ch3 data-end=\"4046\" data-start=\"3979\"\u003e5.2 Re-positioning into metabolic \u0026amp; body-composition programs\u003c\/h3\u003e\n\u003ch4 data-end=\"4070\" data-start=\"4048\"\u003e5.2.1 Rationale\u003c\/h4\u003e\n\u003cp data-end=\"4158\" data-start=\"4071\"\u003eActivin A and myostatin act as \u003cstrong data-end=\"4132\" data-start=\"4102\"\u003eparallel catabolic ligands\u003c\/strong\u003e in muscle. Blocking both:\u003c\/p\u003e\n\u003cul data-end=\"4293\" data-start=\"4160\"\u003e\n\u003cli data-end=\"4195\" data-start=\"4160\"\u003e\n\u003cp data-end=\"4195\" data-start=\"4162\"\u003eenhances lean-mass preservation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4236\" data-start=\"4196\"\u003e\n\u003cp data-end=\"4236\" data-start=\"4198\"\u003eimproves muscle anabolic sensitivity\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4293\" data-start=\"4237\"\u003e\n\u003cp data-end=\"4293\" data-start=\"4239\"\u003eshifts the \u003cstrong data-end=\"4278\" data-start=\"4250\"\u003efat-to-lean partitioning\u003c\/strong\u003e of weight loss\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"4427\" data-start=\"4295\"\u003eThis became highly relevant in the \u003cstrong data-end=\"4343\" data-start=\"4330\"\u003eGLP-1 era\u003c\/strong\u003e, where rapid fat loss is often accompanied by clinically meaningful lean-mass loss.\u003c\/p\u003e\n\u003chr data-end=\"4432\" data-start=\"4429\"\u003e\n\u003ch3 data-end=\"4508\" data-start=\"4434\"\u003e5.2.2 COURAGE Phase 2 trial (semaglutide ± trevogrumab ± garetosmab)\u003c\/h3\u003e\n\u003cp data-end=\"4565\" data-start=\"4510\"\u003eRegeneron’s \u003cstrong data-end=\"4533\" data-start=\"4522\"\u003eCOURAGE\u003c\/strong\u003e program tested combinations of:\u003c\/p\u003e\n\u003cul data-end=\"4670\" data-start=\"4567\"\u003e\n\u003cli data-end=\"4597\" data-start=\"4567\"\u003e\n\u003cp data-end=\"4597\" data-start=\"4569\"\u003e\u003cstrong data-end=\"4595\" data-start=\"4569\"\u003eSemaglutide (GLP-1 RA)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4634\" data-start=\"4598\"\u003e\n\u003cp data-end=\"4634\" data-start=\"4600\"\u003e\u003cstrong data-end=\"4632\" data-start=\"4600\"\u003eTrevogrumab (anti-myostatin)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4670\" data-start=\"4635\"\u003e\n\u003cp data-end=\"4670\" data-start=\"4637\"\u003e\u003cstrong data-end=\"4668\" data-start=\"4637\"\u003eGaretosmab (anti-activin A)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"4716\" data-start=\"4672\"\u003eKey top-line findings reported by Regeneron:\u003c\/p\u003e\n\u003cul data-end=\"5056\" data-start=\"4718\"\u003e\n\u003cli data-end=\"4794\" data-start=\"4718\"\u003e\n\u003cp data-end=\"4794\" data-start=\"4720\"\u003e~35–40% of semaglutide-associated weight loss consisted of \u003cstrong data-end=\"4792\" data-start=\"4779\"\u003elean mass\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4963\" data-start=\"4795\"\u003e\n\u003cp data-end=\"4829\" data-start=\"4797\"\u003eAdding trevogrumab ± garetosmab:\u003c\/p\u003e\n\u003cul data-end=\"4963\" data-start=\"4832\"\u003e\n\u003cli data-end=\"4871\" data-start=\"4832\"\u003e\n\u003cp data-end=\"4871\" data-start=\"4834\"\u003esignificantly \u003cstrong data-end=\"4871\" data-start=\"4848\"\u003epreserved lean mass\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4911\" data-start=\"4874\"\u003e\n\u003cp data-end=\"4911\" data-start=\"4876\"\u003e\u003cstrong data-end=\"4911\" data-start=\"4876\"\u003eincreased proportional fat loss\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4963\" data-start=\"4914\"\u003e\n\u003cp data-end=\"4963\" data-start=\"4916\"\u003eimproved overall \u003cstrong data-end=\"4961\" data-start=\"4933\"\u003ebody-composition quality\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5056\" data-start=\"4964\"\u003e\n\u003cp data-end=\"5056\" data-start=\"4966\"\u003eDual blockade (myostatin + activin A) showed the \u003cstrong data-end=\"5056\" data-start=\"5015\"\u003elargest lean-mass preservation effect\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"5145\" data-start=\"5058\"\u003eThis reframed garetosmab as a \u003cstrong data-end=\"5118\" data-start=\"5088\"\u003ebody-composition optimizer\u003c\/strong\u003e rather than a monotherapy.\u003c\/p\u003e\n\u003chr data-end=\"5150\" data-start=\"5147\"\u003e\n\u003ch2 data-end=\"5210\" data-start=\"5152\"\u003e6) Safety and tolerability: what the biology predicts\u003c\/h2\u003e\n\u003ch3 data-end=\"5254\" data-start=\"5212\"\u003e6.1 Class- and target-informed risks\u003c\/h3\u003e\n\u003cp data-end=\"5362\" data-start=\"5256\"\u003eBecause activin A has broad physiological roles, inhibition carries \u003cstrong data-end=\"5361\" data-start=\"5324\"\u003epredictable domain-specific risks\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5812\" data-start=\"5364\"\u003e\n\u003cthead data-end=\"5408\" data-start=\"5364\"\u003e\n\u003ctr data-end=\"5408\" data-start=\"5364\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5373\" data-start=\"5364\"\u003eSystem\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5387\" data-start=\"5373\"\u003eRisk Signal\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5408\" data-start=\"5387\"\u003eMechanistic Basis\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5812\" data-start=\"5454\"\u003e\n\u003ctr data-end=\"5526\" data-start=\"5454\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5465\" data-start=\"5454\"\u003eVascular\u003c\/td\u003e\n\u003ctd data-end=\"5493\" data-start=\"5465\" data-col-size=\"md\"\u003etelangiectasia, epistaxis\u003c\/td\u003e\n\u003ctd data-end=\"5526\" data-start=\"5493\" data-col-size=\"sm\"\u003eendothelial activin signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5617\" data-start=\"5527\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5542\" data-start=\"5527\"\u003eReproductive\u003c\/td\u003e\n\u003ctd data-end=\"5588\" data-start=\"5542\" data-col-size=\"md\"\u003emenstrual irregularities, fertility effects\u003c\/td\u003e\n\u003ctd data-end=\"5617\" data-start=\"5588\" data-col-size=\"sm\"\u003egonadal activin signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5679\" data-start=\"5618\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5625\" data-start=\"5618\"\u003eBone\u003c\/td\u003e\n\u003ctd data-end=\"5646\" data-start=\"5625\" data-col-size=\"md\"\u003ealtered remodeling\u003c\/td\u003e\n\u003ctd data-end=\"5679\" data-start=\"5646\" data-col-size=\"sm\"\u003eosteoclast\/osteoblast balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5752\" data-start=\"5680\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5698\" data-start=\"5680\"\u003eIron metabolism\u003c\/td\u003e\n\u003ctd data-end=\"5729\" data-start=\"5698\" data-col-size=\"md\"\u003eanemia or iron dysregulation\u003c\/td\u003e\n\u003ctd data-end=\"5752\" data-start=\"5729\" data-col-size=\"sm\"\u003ehepcidin modulation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5812\" data-start=\"5753\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5762\" data-start=\"5753\"\u003eImmune\u003c\/td\u003e\n\u003ctd data-end=\"5786\" data-start=\"5762\" data-col-size=\"md\"\u003ecytokine perturbation\u003c\/td\u003e\n\u003ctd data-end=\"5812\" data-start=\"5786\" data-col-size=\"sm\"\u003eTGF-β family crosstalk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5817\" data-start=\"5814\"\u003e\n\u003ch3 data-end=\"5861\" data-start=\"5819\"\u003e6.2 What FOP trials taught the field\u003c\/h3\u003e\n\u003cp data-end=\"6030\" data-start=\"5862\"\u003eThe FOP program showed that \u003cstrong data-end=\"5930\" data-start=\"5890\"\u003epotent chronic activin A suppression\u003c\/strong\u003e can generate \u003cstrong data-end=\"5988\" data-start=\"5944\"\u003eclinically meaningful safety liabilities\u003c\/strong\u003e, even when biological efficacy is strong.\u003c\/p\u003e\n\u003cp data-end=\"6070\" data-start=\"6032\"\u003eThis is why modern metabolic programs:\u003c\/p\u003e\n\u003cul data-end=\"6247\" data-start=\"6072\"\u003e\n\u003cli data-end=\"6116\" data-start=\"6072\"\u003e\n\u003cp data-end=\"6116\" data-start=\"6074\"\u003euse \u003cstrong data-end=\"6114\" data-start=\"6078\"\u003elower ligand-suppression targets\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6156\" data-start=\"6117\"\u003e\n\u003cp data-end=\"6156\" data-start=\"6119\"\u003eapply \u003cstrong data-end=\"6154\" data-start=\"6125\"\u003eshorter treatment windows\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6247\" data-start=\"6157\"\u003e\n\u003cp data-end=\"6247\" data-start=\"6159\"\u003ecombine garetosmab with myostatin blockade and GLP-1 therapy to reduce required exposure\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6252\" data-start=\"6249\"\u003e\n\u003ch2 data-end=\"6282\" data-start=\"6254\"\u003e7) Regulatory landscape\u003c\/h2\u003e\n\u003cul data-end=\"6551\" data-start=\"6284\"\u003e\n\u003cli data-end=\"6369\" data-start=\"6284\"\u003e\n\u003cp data-end=\"6369\" data-start=\"6286\"\u003e\u003cstrong data-end=\"6319\" data-start=\"6286\"\u003eGaretosmab is investigational\u003c\/strong\u003e and has \u003cstrong data-end=\"6366\" data-start=\"6328\"\u003eno FDA\/EMA marketing authorization\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6433\" data-start=\"6370\"\u003e\n\u003cp data-end=\"6433\" data-start=\"6372\"\u003eDevelopment in FOP was discontinued due to safety concerns.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6551\" data-start=\"6434\"\u003e\n\u003cp data-end=\"6551\" data-start=\"6436\"\u003eCurrent use is limited to \u003cstrong data-end=\"6492\" data-start=\"6462\"\u003econtrolled clinical trials\u003c\/strong\u003e in obesity\/body-composition and related research programs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6556\" data-start=\"6553\"\u003e\n\u003ch2 data-end=\"6630\" data-start=\"6558\"\u003e8) How garetosmab fits into the broader muscle–metabolism landscape\u003c\/h2\u003e\n\u003ch3 data-end=\"6677\" data-start=\"6632\"\u003e8.1 Why activin blockade alone is risky\u003c\/h3\u003e\n\u003cp data-end=\"6780\" data-start=\"6678\"\u003eUnlike myostatin (muscle-dominant), activin A is \u003cstrong data-end=\"6755\" data-start=\"6727\"\u003esystemically pleiotropic\u003c\/strong\u003e. This makes monotherapy:\u003c\/p\u003e\n\u003cul data-end=\"6858\" data-start=\"6782\"\u003e\n\u003cli data-end=\"6807\" data-start=\"6782\"\u003e\n\u003cp data-end=\"6807\" data-start=\"6784\"\u003ebiologically powerful\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6858\" data-start=\"6808\"\u003e\n\u003cp data-end=\"6858\" data-start=\"6810\"\u003eclinically hazardous at chronic full suppression\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6863\" data-start=\"6860\"\u003e\n\u003ch3 data-end=\"6915\" data-start=\"6865\"\u003e8.2 Why it may still succeed in combinations\u003c\/h3\u003e\n\u003cp data-end=\"6980\" data-start=\"6916\"\u003eIn \u003cstrong data-end=\"6967\" data-start=\"6919\"\u003elow-dose, short-course, combination regimens\u003c\/strong\u003e, garetosmab:\u003c\/p\u003e\n\u003cul data-end=\"7095\" data-start=\"6982\"\u003e\n\u003cli data-end=\"7018\" data-start=\"6982\"\u003e\n\u003cp data-end=\"7018\" data-start=\"6984\"\u003eamplifies lean-mass preservation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7053\" data-start=\"7019\"\u003e\n\u003cp data-end=\"7053\" data-start=\"7021\"\u003eimproves fat-loss partitioning\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7095\" data-start=\"7054\"\u003e\n\u003cp data-end=\"7095\" data-start=\"7056\"\u003ereduces the dose burden on each pathway\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7234\" data-start=\"7097\"\u003eThis \u003cstrong data-end=\"7145\" data-start=\"7102\"\u003epoly-agonist \/ poly-blockade philosophy\u003c\/strong\u003e mirrors what succeeded in incretin pharmacology (e.g., GLP-1\/GIP\/glucagon tri-agonists).\u003c\/p\u003e\n\u003chr data-end=\"7239\" data-start=\"7236\"\u003e\n\u003ch2 data-end=\"7291\" data-start=\"7241\"\u003e9) Future directions and decisive experiments\u003c\/h2\u003e\n\u003cp data-end=\"7385\" data-start=\"7293\"\u003eTo justify a long-term role for garetosmab in metabolic medicine, the following are pivotal:\u003c\/p\u003e\n\u003col data-end=\"7886\" data-start=\"7387\"\u003e\n\u003cli data-end=\"7511\" data-start=\"7387\"\u003e\n\u003cp data-end=\"7511\" data-start=\"7390\"\u003e\u003cstrong data-end=\"7422\" data-start=\"7390\"\u003eExposure–safety optimization\u003c\/strong\u003e\u003cbr data-end=\"7425\" data-start=\"7422\"\u003eIdentify the minimum activin A suppression needed for meaningful lean-mass benefit.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7622\" data-start=\"7513\"\u003e\n\u003cp data-end=\"7622\" data-start=\"7516\"\u003e\u003cstrong data-end=\"7544\" data-start=\"7516\"\u003eFunction-first endpoints\u003c\/strong\u003e\u003cbr data-end=\"7547\" data-start=\"7544\"\u003eStrength, power, VO₂peak, frailty indices, falls—not just DXA lean mass.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7774\" data-start=\"7624\"\u003e\n\u003cp data-end=\"7653\" data-start=\"7627\"\u003e\u003cstrong data-end=\"7651\" data-start=\"7627\"\u003ePopulation targeting\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"7774\" data-start=\"7657\"\u003e\n\u003cli data-end=\"7690\" data-start=\"7657\"\u003e\n\u003cp data-end=\"7690\" data-start=\"7659\"\u003eolder adults on GLP-1 therapy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7729\" data-start=\"7694\"\u003e\n\u003cp data-end=\"7729\" data-start=\"7696\"\u003epost-hospitalization sarcopenia\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7774\" data-start=\"7733\"\u003e\n\u003cp data-end=\"7774\" data-start=\"7735\"\u003elow-muscle-reserve obesity phenotypes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7886\" data-start=\"7776\"\u003e\n\u003cp data-end=\"7886\" data-start=\"7779\"\u003e\u003cstrong data-end=\"7812\" data-start=\"7779\"\u003eMechanistic biomarker mapping\u003c\/strong\u003e\u003cbr data-end=\"7815\" data-start=\"7812\"\u003eSMAD2\/3 signatures, muscle protein synthesis, iron\/hepcidin markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-end=\"7891\" data-start=\"7888\"\u003e\n\u003ch2 data-end=\"7944\" data-start=\"7893\"\u003eSelected references (most directly supportive)\u003c\/h2\u003e\n\u003cul data-end=\"8339\" data-start=\"7946\"\u003e\n\u003cli data-end=\"8040\" data-start=\"7946\"\u003e\n\u003cp data-end=\"8040\" data-start=\"7948\"\u003eGaretosmab FOP program overview and activin A targeting rationale — Regeneron publications\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8110\" data-start=\"8041\"\u003e\n\u003cp data-end=\"8110\" data-start=\"8043\"\u003eLUMINA-1 Phase 2 trial in FOP (HO suppression and safety signals)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8204\" data-start=\"8111\"\u003e\n\u003cp data-end=\"8204\" data-start=\"8113\"\u003eCOURAGE Phase 2 trial (semaglutide ± trevogrumab ± garetosmab) — Regeneron press releases\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8289\" data-start=\"8205\"\u003e\n\u003cp data-end=\"8289\" data-start=\"8207\"\u003e\u003cem data-end=\"8224\" data-start=\"8207\"\u003eCell Metabolism\u003c\/em\u003e 2025: GDF-8 and activin A blockade combined with GLP-1 therapy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8339\" data-start=\"8290\"\u003e\n\u003cp data-end=\"8339\" data-start=\"8292\"\u003eTGF-β superfamily \/ activin A biology reviews\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8344\" data-start=\"8341\"\u003e\n\u003ch2 data-end=\"8387\" data-start=\"8346\"\u003eBottom line (scientific positioning)\u003c\/h2\u003e\n\u003cp data-end=\"8807\" data-start=\"8389\"\u003eGaretosmab is a \u003cstrong data-end=\"8452\" data-start=\"8405\"\u003ebiologically potent but clinically delicate\u003c\/strong\u003e activin A–neutralizing antibody. Its initial failure in FOP highlights the \u003cstrong data-end=\"8580\" data-start=\"8528\"\u003erisks of chronic, high-level activin suppression\u003c\/strong\u003e, while its re-emergence in GLP-1 combination regimens illustrates a \u003cstrong data-end=\"8679\" data-start=\"8649\"\u003enew therapeutic philosophy\u003c\/strong\u003e: use narrowly dosed pathway modulators to optimize \u003cstrong data-end=\"8759\" data-start=\"8731\"\u003ebody-composition quality\u003c\/strong\u003e rather than pursue maximal monotherapy effects.\u003c\/p\u003e\n\u003cp data-end=\"8975\" data-start=\"8809\"\u003eIf successful, garetosmab’s future will not be as a stand-alone drug—but as a \u003cstrong data-end=\"8908\" data-start=\"8887\"\u003eprecision adjunct\u003c\/strong\u003e in next-generation metabolic and sarcopenia-prevention strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684842991954,"sku":null,"price":5000.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Garetosmab_10mg.png?v=1770834808","url":"https:\/\/sciencepeptideslab.com\/products\/garetosmab-regn2477-10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}